MolecuLight Showcases Innovations in Wound Care Imaging at SAWC Fall 2025

MolecuLight Inc., an industry leader in fluorescence imaging for wound care, recently made headlines with its participation at the SAWC Fall 2025, held from September 3-6 in Las Vegas, Nevada. As a hub for clinical professionals and researchers focused on advancing patient care, SAWC Fall featured a multitude of innovations from MolecuLight, notably presenting ten scientific posters that delve into a range of clinical applications of its multimodal imaging platform.

A Platform of Advances

The MolecuLightDX®+ device, which attendees could see in action at Booth #327, stands as a comprehensive, portable imaging platform designed for several applications in wound care. Here, healthcare providers can detect bacteria, assess wound measurements, and analyze thermal images—all from a single device. The posters presented cover crucial areas such as:

1. Patient Engagement and Education: Enhancing communication and shared decision-making through imaging.
2. Intraoperative and Preoperative Use: Providing surgical teams with real-time wound information.
3. Wound Hygiene and Debridement: Improving debridement practices by identifying bacterial hotspots.
4. Thermal Imaging in Wound Care: Exploring the role of thermal mapping for objective wound assessment.

These applications highlight how MolecuLight's innovations aim to transform the traditional methods of evaluating and managing wounds, improving outcomes for patients and clinicians alike.

Introducing Oxygenation Imaging

Perhaps the most significant announcement was the upcoming introduction of oxygenation imaging capabilities on the MolecuLightDX®+ platform. Set for FDA submission in Q4 2025, this new feature will allow clinicians to assess oxygenation levels in wounds, monitor bacterial load, precisely measure wound dimensions, and observe thermal changes—all through one compact and portable unit. This integration not only streamlines the workflow but also enhances documentation efficiency for healthcare providers.

Anil Amlani, CEO of MolecuLight, expressed pride in the company's contributions to the SAWC Fall conference, stating, “Our platform is significantly evolving the wound assessment process; it’s about enhancing patient engagement, providing detailed intraoperative guidance, facilitating improved debridement practices, and introducing innovative thermal imaging perspectives.”

Unifying Clinical Efficiencies

The MolecuLightDX®+ not only simplifies wound assessment but also effortlessly integrates with leading electronic medical records systems, such as Epic. This functionality is designed to boost clinical efficiency and expedite workflows. Additionally, as a HIPAA-compliant and SOC 2 certified device, it is validated through a robust body of evidence, including over 100 peer-reviewed publications, ensuring confidence in its application across various wound types in any healthcare setting.

Furthermore, the MolecuLight team anticipates receiving the Medical Device Development Tool (MDDT) designation from the FDA this fall for their wound measurement technology. This approval would further substantiate the accuracy and reliability of their wound measurement solutions, positioning them as pivotal tools in clinical trials for other wound care products.

The Impact on Wound Care

As SAWC Fall continues to serve as a premier platform for advancing wound care, MolecuLight’s participation demonstrates its commitment to pushing the boundaries of what’s possible in patient care. The wide-ranging applications highlighted through the ten scientific posters showcase the company’s dedication to innovation, transforming wound assessment and management for healthcare professionals worldwide.

Attendees are encouraged to visit MolecuLight at Booth #327, where they can witness live demonstrations of the MolecuLightDX®+ technology and understand how it can reshape clinical practices related to wound evaluation, documentation, and patient outcomes.

About MolecuLight

MolecuLight is a global leader in medical imaging, dedicated to developing technologies that enhance wound care. With FDA-approved devices like the MolecuLight iX® and DX®, the company is committed to providing real-time insights into wound management, all backed by a significant volume of clinical research, ensuring the utmost reliability and effectiveness in patient treatment.

For more information, visit www.moleculight.com.